1478 related articles for article (PubMed ID: 14576837)
21. alpha-TEA inhibits survival and enhances death pathways in cisplatin sensitive and resistant human ovarian cancer cells.
Yu W; Shun MC; Anderson K; Chen H; Sanders BG; Kline K
Apoptosis; 2006 Oct; 11(10):1813-23. PubMed ID: 16850165
[TBL] [Abstract][Full Text] [Related]
22. Mutations in DNA mismatch repair genes: implications for DNA damage signaling and drug sensitivity (review).
Fedier A; Fink D
Int J Oncol; 2004 Apr; 24(4):1039-47. PubMed ID: 15010846
[TBL] [Abstract][Full Text] [Related]
23. Induction of p53-mediated apoptosis and recovery of chemosensitivity through p53 transduction in human glioblastoma cells by cisplatin.
Park CM; Park MJ; Kwak HJ; Moon SI; Yoo DH; Lee HC; Park IC; Rhee CH; Hong SI
Int J Oncol; 2006 Jan; 28(1):119-25. PubMed ID: 16327987
[TBL] [Abstract][Full Text] [Related]
24. Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance.
Brenes O; Arce F; Gätjens-Boniche O; Díaz C
Biomed Pharmacother; 2007 Jul; 61(6):347-55. PubMed ID: 17399942
[TBL] [Abstract][Full Text] [Related]
25. A conserved RAS/mitogen-activated protein kinase pathway regulates DNA damage-induced cell death postirradiation in Radelegans.
Weidhaas JB; Eisenmann DM; Holub JM; Nallur SV
Cancer Res; 2006 Nov; 66(21):10434-8. PubMed ID: 17079464
[TBL] [Abstract][Full Text] [Related]
26. Loss of caspase-8 activation pathway is a possible mechanism for CDDP resistance in human laryngeal squamous cell carcinoma, HEp-2 cells.
Toyozumi Y; Arima N; Izumaru S; Kato S; Morimatsu M; Nakashima T
Int J Oncol; 2004 Sep; 25(3):721-8. PubMed ID: 15289875
[TBL] [Abstract][Full Text] [Related]
27. Nitric oxide regulates cell sensitivity to cisplatin-induced apoptosis through S-nitrosylation and inhibition of Bcl-2 ubiquitination.
Chanvorachote P; Nimmannit U; Stehlik C; Wang L; Jiang BH; Ongpipatanakul B; Rojanasakul Y
Cancer Res; 2006 Jun; 66(12):6353-60. PubMed ID: 16778213
[TBL] [Abstract][Full Text] [Related]
28. Expression of kinase suppressor of Ras1 enhances cisplatin-induced extracellular signal-regulated kinase activation and cisplatin sensitivity.
Kim M; Yan Y; Kortum RL; Stoeger SM; Sgagias MK; Lee K; Lewis RE; Cowan KH
Cancer Res; 2005 May; 65(10):3986-92. PubMed ID: 15899786
[TBL] [Abstract][Full Text] [Related]
29. Resistance to Fas-mediated apoptosis in malignant tumours is rescued by KN-93 and cisplatin via downregulation of c-FLIP expression and phosphorylation.
Yang BF; Xiao C; Li H; Yang SJ
Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1245-51. PubMed ID: 17973862
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of DNA methyltransferase reverses cisplatin induced drug resistance in murine neuroblastoma cells.
Qiu YY; Mirkin BL; Dwivedi RS
Cancer Detect Prev; 2005; 29(5):456-63. PubMed ID: 16185816
[TBL] [Abstract][Full Text] [Related]
31. Avoidance of apoptosis as a mechanism of drug resistance.
Dive C
J Intern Med Suppl; 1997; 740():139-45. PubMed ID: 9350196
[TBL] [Abstract][Full Text] [Related]
32. Molecular mechanisms of cisplatin resistance in bladder cancer.
Drayton RM; Catto JW
Expert Rev Anticancer Ther; 2012 Feb; 12(2):271-81. PubMed ID: 22316374
[TBL] [Abstract][Full Text] [Related]
33. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review).
Wang G; Reed E; Li QQ
Oncol Rep; 2004 Nov; 12(5):955-65. PubMed ID: 15492778
[TBL] [Abstract][Full Text] [Related]
34. Molecular basis of cis-diamminedichloroplatinum(II) resistance: a review.
Chao CC
J Formos Med Assoc; 1996 Dec; 95(12):893-900. PubMed ID: 9000804
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin resistance and oncogenes--a review.
Dempke W; Voigt W; Grothey A; Hill BT; Schmoll HJ
Anticancer Drugs; 2000 Apr; 11(4):225-36. PubMed ID: 10898536
[TBL] [Abstract][Full Text] [Related]
36. Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways.
Sedletska Y; Giraud-Panis MJ; Malinge JM
Curr Med Chem Anticancer Agents; 2005 May; 5(3):251-65. PubMed ID: 15992353
[TBL] [Abstract][Full Text] [Related]
37. Cisplatin.
Reed E
Cancer Chemother Biol Response Modif; 1999; 18():144-51. PubMed ID: 10800481
[No Abstract] [Full Text] [Related]
38. Mechanisms of Cisplatin-Induced Apoptosis and of Cisplatin Sensitivity: Potential of BIN1 to Act as a Potent Predictor of Cisplatin Sensitivity in Gastric Cancer Treatment.
Tanida S; Mizoshita T; Ozeki K; Tsukamoto H; Kamiya T; Kataoka H; Sakamuro D; Joh T
Int J Surg Oncol; 2012; 2012():862879. PubMed ID: 22778941
[TBL] [Abstract][Full Text] [Related]
39. Screening for modulators of cisplatin sensitivity: unbiased screens reveal common themes.
Nijwening JH; Kuiken HJ; Beijersbergen RL
Cell Cycle; 2011 Feb; 10(3):380-6. PubMed ID: 21239890
[TBL] [Abstract][Full Text] [Related]
40. Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance.
Fuertes MA; Alonso C; Pérez JM
Chem Rev; 2003 Mar; 103(3):645-62. PubMed ID: 12630848
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
